Biogen reported heavily anticipated Alzheimer’s data, saying its tau-targeting drug BIIB080 missed its primary endpoint in a Phase 2 study but showed other signs of benefit.
Here we go again?
Biogen reported heavily anticipated Alzheimer’s data, saying its tau-targeting drug BIIB080 missed its primary endpoint in a Phase 2 study but …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Biogen pushing tau drug forward despite Alzheimer’s study failure
Biogen advances Alzheimer's drug to late-stage trial despite disappointing data
Biogen's tau-targeting Alzheimer's drug posts mixed results in mid-stage study
Astellas treatment offers new hope to a devastated rare disease community
Eisai's slow push toward blockbuster Leqembi sales gains steam with $900M forecast
Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial
A year after Vertex’s big launch, pain drug research faces a pivotal moment
Medicare is spending far less than expected on new Alzheimer’s drugs
BeOne wins FDA approval in lymphoma race
One of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the strength of…
Biogen said signals sugget the treatment decreases levels of tau and slows cognitive decline, particularly at the lowest dose.
Biogen is moving its tau-targeting Alzheimer's drug into Phase 3 studies, despite mixed data from a Phase 2 trial.
Stifel sees Biogen stock rallying nearly 32% from here.
Alzheimer's drug rollout letdown, a China-based heart drug startup, and more biotech news from The Readout
Scientists and doctors remain divided on the targeted antibody drugs that slow down the early stages of Alzheimer’s
